Loading...
XNASMNKD
Market cap1.94bUSD
Dec 23, Last price  
7.02USD
1D
2.48%
1Q
8.17%
Jan 2017
120.55%
Name

MannKind Corp

Chart & Performance

D1W1MN
XNAS:MNKD chart
P/E
—
P/S
9.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.12%
Rev. gr., 5y
48.17%
Revenues
199m
+99.42%
00100,00010,00020,000093,00050,00035,000000174,758,00011,745,00027,859,00063,038,00065,144,00075,442,00099,770,000198,962,000
Net income
-12m
L-89.36%
-75,992,000-114,338,000-230,548,000-293,190,000-303,039,000-220,104,000-170,560,000-160,804,000-169,366,000-191,490,000-198,382,000-368,445,000125,664,000-117,333,000-86,975,000-59,729,000-57,240,000-91,791,000-112,169,000-11,938,000
CFO
34m
P
-59,911,000-101,229,000-189,794,000-245,146,000-271,288,000-184,083,000-148,654,000-123,837,000-119,860,000-128,732,0004,086,000-57,232,000-78,090,000-64,778,000-37,731,000-88,483,000-28,128,000-61,709,000-80,679,00034,094,000
Earnings
Feb 25, 2025

Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
URL
https://mannkindcorp.com/
IPO date
Jul 28, 2004
Employees
391
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
198,962
99.42%
99,770
32.25%
75,442
15.81%
Cost of revenue
188,368
168,691
128,586
Unusual Expense (Income)
NOPBT
10,594
(68,921)
(53,144)
NOPBT Margin
5.32%
Operating Taxes
1,561
24,769
10,865
Tax Rate
14.73%
NOPAT
9,033
(93,690)
(64,009)
Net income
(11,938)
-89.36%
(112,169)
22.20%
(91,791)
60.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,887
22,556
(1,626)
BB yield
-0.71%
-1.66%
0.15%
Debt
Debt current
31,984
9,565
6,977
Long-term debt
445,187
378,688
376,807
Deferred revenue
69,794
37,684
24,493
Other long-term liabilities
200,504
67,495
81,497
Net debt
174,917
215,446
123,049
Cash flow
Cash from operating activities
34,094
(80,679)
(61,709)
CAPEX
(42,441)
(7,589)
(11,466)
Cash from investing activities
(1,988)
4,874
(151,537)
Cash from financing activities
136,607
21,406
270,267
FCF
(28,427)
(108,523)
(74,754)
Balance
Cash
295,099
170,846
204,116
Long term investments
7,155
1,961
56,619
Excess cash
292,306
167,818
256,963
Stockholders' equity
(3,226,707)
(3,214,831)
(3,127,554)
Invested Capital
3,617,780
3,452,382
3,406,939
ROIC
0.26%
ROCE
2.71%
EV
Common stock shares outstanding
267,014
257,092
249,244
Price
3.64
-30.93%
5.27
20.59%
4.37
39.62%
Market cap
971,931
-28.26%
1,354,875
24.39%
1,089,196
56.34%
EV
1,146,848
1,570,321
1,212,245
EBITDA
16,430
(59,810)
(47,671)
EV/EBITDA
69.80
Interest
25,161
24,769
16,577
Interest/NOPBT
237.50%